A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater access to heart transplants. Xvivo Perfusion, a leader in organ transplant ...

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

27 April 2025, Boston—In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn’t get the organ to ...

In the United States, about 30-40% of donor hearts aren't considered for transplant due to inadequate function in the donor. This leads to a drop in the number of donated hearts that are available to ...

Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of ...

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...

GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ...

The global perfusion systems market is largely fueled by the increasing prevalence of cardiovascular disorders and the growing number of cardiac surgeries performed worldwide. In addition, the rising ...